Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era

Br J Haematol. 2023 Feb;200(4):524-527. doi: 10.1111/bjh.18590. Epub 2022 Dec 9.
No abstract available

Keywords: diffuse large B cell lymphoma; ocular adnexa; orbit; outcomes; radiation; rituximab; treatment.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Rituximab / therapeutic use

Substances

  • Rituximab
  • Antibodies, Monoclonal, Murine-Derived